Genetic Mapping of Interactive Susceptibility Loci in Patients and Siblings with Breast, Colon, Lung, or Prostate Cancer
Last Modified: 3/18/2008 First Published: 9/1/1998
Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information
Alternate Title
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| No phase specified | Genetics | Completed | Not specified | ECOG-1Y97
E1Y97, NCT00003329 |
Objectives - Gather allele-sharing statistics at approximately 100 candidate loci throughout the human genome most likely to influence genetic risk of cancer.
- Use these allele-sharing statistics to test the interaction of each locus individually with cancer-associated, rare alleles of HRAS1.
- Generalize this approach for one of four cancers (breast, colon, lung, or prostate), using allele-sharing statistics to test the interaction of each locus with every other locus.
- Replicate positive results in a distinct set of sibling pairs with cancer.
- Examine, when loci contributing to risk are detected, the influence of this genetic background on clinical outcomes, such as survival.
Entry Criteria Disease Characteristics:
- Histologically confirmed colon, lung, prostate, or invasive breast cancer
- No ductal or lobular carcinoma in situ of the breast
only
- Patient and natural full sibling must have (or have had) cancer of the
same
type
- Participants in E-3Y92 not eligible
- Hormone receptor status:
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy Endocrine therapy Radiotherapy Surgery Patient Characteristics:
Age: Menopausal status: Performance status: Life expectancy: Hematopoietic: Hepatic: Renal: Expected Enrollment 4000This study will accrue 1,000 patient-sibling pairs for breast cancer. After
18 months, another 1,000 patient-sibling pairs will be accrued for breast
cancer. Therefore, up to 2,000 patient-sibling pairs will be accrued over 5
years. (Feasibility of accruing pairs for lung, colon, and prostate cancer is
being assessed.) Outline Each patient-sibling pair completes a family history questionnaire about
the incidence of cancer in the family. Blood samples are obtained from both
the patient and the sibling (and both living parents, if available). The blood samples are genotyped using approximately 300 micro-satellite
markers flanking 100 candidate genes previously implicated in genetic risk for
cancer. Certain loci are a priority due to their association with HRAS1:
BRCA1 and all known mismatch repair loci; other repair genes, such as ATM; the
Bloom's syndrome locus; and the XRCC group. Other genes are also
mapped. Patients do not receive the results of the genetic testing and the
results do not influence the type and duration of treatment. Patients only are followed annually. Published ResultsLarson GP, Ding Y, Cheng LS, et al.: Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res 65 (3): 805-14, 2005.[PUBMED Abstract] Krontiris TG, Larson M, Weitzel JN, et al.: Mapping interactive cancer susceptibility loci: Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A2147, 560a, 1998.
Trial Contact Information
Trial Lead Organizations Eastern Cooperative Oncology Group  | | | | Clinical Trials Office - New Patient Services | | | |
| Registry Information | | | Official Title | | ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci | | | Trial Start Date | | 1998-01-30 | | | Trial Completion Date | | 2007-12-27 | | | Registered in ClinicalTrials.gov | | NCT00003329 1 | | | Date Submitted to PDQ | | 1998-02-11 | | | Information Last Verified | | 2008-03-06 | | | NCI Grant/Contract Number | | CA21115 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.
Table of Links
| 1 | http://clinicaltrials.gov/ct/show/NCT00003329 |
|
